cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.14696513
title: US E-Cigarette Market 2024 To 2033

description: US E-Cigarette Market Size, Trends and Insights By Type of Device (Modular E-Cigarette, Rechargeable E-Cigarette, Next-Generation E-Cigarette, Disposable E-Cigarette), By Flavor (Tobacco, Botanical, Fruit, Sweet, Beverage, Others), By Mode of Operation (Automatic E-Cigarette, Manual E-Cigarette), By Distribution Channel (Specialty E-Cig Shops, Online, Supermarkets and Hypermarkets, Tobacconist, Others), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033.

Reports Description

As per the current market research conducted by the CMI Team, the US E-Cigarette Market is expected to record a CAGR of 8.7% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 527.4 Million. By 2033, the valuation is anticipated to reach USD 1,117.4 Million.

Growth rates for e-cigarettes in the U.S. are growing rapidly, mainly because of flavored products and customized devices appealing to more young adults, giving an illusion of a safer alternative to traditional cigarettes. Innovative technology, such as advanced temperature controls, continues to improve the vaping experience.

E-commerce sales grow, with full potential for increased business as consumers shift for convenience. Regulatory issues, particularly concerning flavored products, are now shaping the market. Companies such as Altria and Philip Morris are reacting by extending their respective lines of products. The market related to electronic cigarettes will continue to grow strongly in the years to come due to consumer preferences changing over time toward a safer option.

For more information, DOWNLOAD FREE SAMPLE Now at https://www.custommarketinsights.com/request-for-free-sample/?reportid=59721
DOI: 10.5281/zenodo.14696514
title: US E-Cigarette Market 2024 To 2033

description: US E-Cigarette Market Size, Trends and Insights By Type of Device (Modular E-Cigarette, Rechargeable E-Cigarette, Next-Generation E-Cigarette, Disposable E-Cigarette), By Flavor (Tobacco, Botanical, Fruit, Sweet, Beverage, Others), By Mode of Operation (Automatic E-Cigarette, Manual E-Cigarette), By Distribution Channel (Specialty E-Cig Shops, Online, Supermarkets and Hypermarkets, Tobacconist, Others), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033.

Reports Description

As per the current market research conducted by the CMI Team, the US E-Cigarette Market is expected to record a CAGR of 8.7% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 527.4 Million. By 2033, the valuation is anticipated to reach USD 1,117.4 Million.

Growth rates for e-cigarettes in the U.S. are growing rapidly, mainly because of flavored products and customized devices appealing to more young adults, giving an illusion of a safer alternative to traditional cigarettes. Innovative technology, such as advanced temperature controls, continues to improve the vaping experience.

E-commerce sales grow, with full potential for increased business as consumers shift for convenience. Regulatory issues, particularly concerning flavored products, are now shaping the market. Companies such as Altria and Philip Morris are reacting by extending their respective lines of products. The market related to electronic cigarettes will continue to grow strongly in the years to come due to consumer preferences changing over time toward a safer option.

For more information, DOWNLOAD FREE SAMPLE Now at https://www.custommarketinsights.com/request-for-free-sample/?reportid=59721
DOI: 10.15468/dl.d2hab9
title: Occurrence Download

description: A dataset containing 353350 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is iNaturalist Research-grade Observations",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Country is one of (Canada, Mexico, United States of America)",
 "EventDate is greater than or equal to 2024-11-26",
 "EventDate is less than or equal to 2024-12-26",
 {
 "not" : {
 "Issue" : [
 "is one of (Basis of record invalid, Coordinate reprojection failed, Coordinate reprojection suspicious, Coordinate precision invalid, Coordinate uncertainty meters invalid, Country mismatch, Country invalid, Geodetic datum invalid, Presumed swapped coordinate, Presumed negated longitude, Presumed negated latitude, Country coordinate mismatch)"
 ]
 }
 }
 ]
}

 The dataset includes 353350 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0000785-250121130708018/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.14715725
title: Global Scented Candles Market 2024 To 2033

description: Scented Candles Market Size, Trends and Insights By Product Type (Container-Based Scented Candles, Pillar Scented Candles, Taper Scented Candles, Tea Light Scented Candles, Others (Votive, Floating, etc.)), By Wax Type (Paraffin Wax, Soy Wax, Beeswax, Palm Wax, Coconut Wax, Blended Wax, Others (Gel Wax, Bayberry Wax, etc.)), By Category (Mass, Premium), By Distribution Channel (Online, Offline), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033

Reports Description

Global Scented Candles Market size was valued at USD 3.88 Billion in 2024 and is expected to reach at USD 5.68 Billion by 2033 at a CAGR of 5.2% during the forecast period 2024 – 2033. 

Scented candles are a type of decorative candle that is made with fragrance. The scent would get released upon burning the candle. These candles have their own unique meaning; not only do they provide light, but they also have a scented atmosphere.

Their most common use is in residences, spas, or hospitality, which can be used for relaxation, aromatherapy, or as a gift. The development of home décor, wellness, and personal fragrance demands has been the main driving force for the global scented candles market.

The availability of premium products such as eco-friendly wax and unique designs has also impacted the market. Furthermore, the e-commerce development, as well as the seasonal and thematic collections, have greatly widened the scope and attractiveness of the market.

For more information, DOWNLOAD FREE SAMPLE Now at https://www.custommarketinsights.com/request-for-free-sample/?reportid=59892
DOI: 10.5281/zenodo.14715726
title: Global Scented Candles Market 2024 To 2033

description: Scented Candles Market Size, Trends and Insights By Product Type (Container-Based Scented Candles, Pillar Scented Candles, Taper Scented Candles, Tea Light Scented Candles, Others (Votive, Floating, etc.)), By Wax Type (Paraffin Wax, Soy Wax, Beeswax, Palm Wax, Coconut Wax, Blended Wax, Others (Gel Wax, Bayberry Wax, etc.)), By Category (Mass, Premium), By Distribution Channel (Online, Offline), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033

Reports Description

Global Scented Candles Market size was valued at USD 3.88 Billion in 2024 and is expected to reach at USD 5.68 Billion by 2033 at a CAGR of 5.2% during the forecast period 2024 – 2033. 

Scented candles are a type of decorative candle that is made with fragrance. The scent would get released upon burning the candle. These candles have their own unique meaning; not only do they provide light, but they also have a scented atmosphere.

Their most common use is in residences, spas, or hospitality, which can be used for relaxation, aromatherapy, or as a gift. The development of home décor, wellness, and personal fragrance demands has been the main driving force for the global scented candles market.

The availability of premium products such as eco-friendly wax and unique designs has also impacted the market. Furthermore, the e-commerce development, as well as the seasonal and thematic collections, have greatly widened the scope and attractiveness of the market.

For more information, DOWNLOAD FREE SAMPLE Now at https://www.custommarketinsights.com/request-for-free-sample/?reportid=59892
DOI: 10.34740/kaggle/dsv/10544893
title: Layline Shareholder activism dataset
DOI: 10.5281/zenodo.11650268
title: Dataset for: Conventional and organic farms with more intensive management have lower soil functionality

description: Datafiles and R code for the manuscript “Conventional and organic farms with more intensive management have lower soil functionality”

Authors: Sophie Q. van Rijssel, Guusje J. Koorneef, G.F. (Ciska) Veen, Mirjam M. Pulleman, Ron G.M. de Goede, Rob N.J. Comans, Wim H. van der Putten, & Kyle Mason-Jones
DOI: 10.5281/zenodo.11650269
title: Dataset for: Conventional and organic farms with more intensive management have lower soil functionality

description: Datafiles and R code for the manuscript “Conventional and organic farms with more intensive management have lower soil functionality”

Authors: Sophie Q. van Rijssel, Guusje J. Koorneef, G.F. (Ciska) Veen, Mirjam M. Pulleman, Ron G.M. de Goede, Rob N.J. Comans, Wim H. van der Putten, & Kyle Mason-Jones
DOI: 10.6084/m9.figshare.26977836
title: Association of life’s essential 8 and asthma: mediating effect of inflammation and oxidative stress

description: The association of cardiovascular health (CVH) with asthma risk in U.S. adults remains unclear. This study aimed to explore the association of Life’s Essential 8 (LE8), a measurement of CVH, with asthma and investigate the potential mediating effect of inflammation and oxidative stress. The data was obtained from the National Health and Nutrition Examination Survey (NHANES) in 2005–2018. LE8 score (range 0 ∼ 100) was measured and categorized as low (&lt;50), moderate (50 ∼ &lt;80), and high (≥80) CVH. Survey-weighted logistic regression and restricted cubic spline model were employed to explore the association between LE8 score and asthma. Mediation analyses were conducted to identify the mediating effects of inflammation and oxidative stress biomarkers. This study included 10,932 participants aged ≥ 20 years, among whom 890 (8.14%) reported prevalent asthma. After adjusting for all covariates, the odd ratios (OR) for asthma were 0.67 (95% confidence interval (CI): 0.48, 0.94) in the moderate CVH group and 0.52 (95% CI: 0.34, 0.79) in the high CVH group compared with the low CVH group, respectively. The OR for asthma was 0.85 (95% CI: 0.78, 0.93) for every 10 score increase in LE8 score, and linear dose-response relationship was observed (<i>p =</i> 0.0642). Mediation analyses showed that inflammation and oxidative stress mediated 15.97% and 11.50% of the association between LE8 score and asthma, respectively (all <i>p</i> &lt; 0.05). LE8 score was negatively associated with asthma, and inflammation and oxidative stress partially mediated this association. It is recommended that maintaining optimal CVH may prevent asthma.
DOI: 10.6084/m9.figshare.26977836.v1
title: Association of life’s essential 8 and asthma: mediating effect of inflammation and oxidative stress

description: The association of cardiovascular health (CVH) with asthma risk in U.S. adults remains unclear. This study aimed to explore the association of Life’s Essential 8 (LE8), a measurement of CVH, with asthma and investigate the potential mediating effect of inflammation and oxidative stress. The data was obtained from the National Health and Nutrition Examination Survey (NHANES) in 2005–2018. LE8 score (range 0 ∼ 100) was measured and categorized as low (&lt;50), moderate (50 ∼ &lt;80), and high (≥80) CVH. Survey-weighted logistic regression and restricted cubic spline model were employed to explore the association between LE8 score and asthma. Mediation analyses were conducted to identify the mediating effects of inflammation and oxidative stress biomarkers. This study included 10,932 participants aged ≥ 20 years, among whom 890 (8.14%) reported prevalent asthma. After adjusting for all covariates, the odd ratios (OR) for asthma were 0.67 (95% confidence interval (CI): 0.48, 0.94) in the moderate CVH group and 0.52 (95% CI: 0.34, 0.79) in the high CVH group compared with the low CVH group, respectively. The OR for asthma was 0.85 (95% CI: 0.78, 0.93) for every 10 score increase in LE8 score, and linear dose-response relationship was observed (<i>p =</i> 0.0642). Mediation analyses showed that inflammation and oxidative stress mediated 15.97% and 11.50% of the association between LE8 score and asthma, respectively (all <i>p</i> &lt; 0.05). LE8 score was negatively associated with asthma, and inflammation and oxidative stress partially mediated this association. It is recommended that maintaining optimal CVH may prevent asthma.
DOI: 10.6084/m9.figshare.26963428
title: Exploring the mechanisms and relationship between body mass index and asthma: findings from Mendelian randomization

description: The mechanism linking BMI and asthma remains unclear. Mendelian Randomization (MR) analysis was conducted using summary-level GWAS data from the FinnGen Biobank and the Open GWAS project. The analysis considering potential variables as mediators, including blood cell counts, blood pressure, and blood biomarkers. Three commonly used MR methods—the inverse-variance-weighted (IVW) method, weighted median (WM) method, and MR-Egger method—were employed to infer causal links. A two-step approach was used in mediation analysis to evaluate the causal links among BMI, candidate mediators, and asthma. Elevated BMI demonstrated a substantial correlation with increased asthma risk. Thirteen biomarkers mediated the relationship between BMI and asthma, mainly including leukocyte count (5.070%), apolipoprotein A levels (7.395%), cystatin C levels (5.345%), urate levels (9.057%), diastolic blood pressure (7.365%), and albumin levels (10.888%). These factors collectively explained over 50% of the increased asthma risk associated with BMI elevation. Additionally, eosinophil count and C-reactive protein were also identified as important mediators using the WM method. This study highlights the complex relationship between obesity, blood biomarkers, and asthma risk. Additional studies are required to validate these results and investigate causal relationships in various populations.
DOI: 10.6084/m9.figshare.26963428.v1
title: Exploring the mechanisms and relationship between body mass index and asthma: findings from Mendelian randomization

description: The mechanism linking BMI and asthma remains unclear. Mendelian Randomization (MR) analysis was conducted using summary-level GWAS data from the FinnGen Biobank and the Open GWAS project. The analysis considering potential variables as mediators, including blood cell counts, blood pressure, and blood biomarkers. Three commonly used MR methods—the inverse-variance-weighted (IVW) method, weighted median (WM) method, and MR-Egger method—were employed to infer causal links. A two-step approach was used in mediation analysis to evaluate the causal links among BMI, candidate mediators, and asthma. Elevated BMI demonstrated a substantial correlation with increased asthma risk. Thirteen biomarkers mediated the relationship between BMI and asthma, mainly including leukocyte count (5.070%), apolipoprotein A levels (7.395%), cystatin C levels (5.345%), urate levels (9.057%), diastolic blood pressure (7.365%), and albumin levels (10.888%). These factors collectively explained over 50% of the increased asthma risk associated with BMI elevation. Additionally, eosinophil count and C-reactive protein were also identified as important mediators using the WM method. This study highlights the complex relationship between obesity, blood biomarkers, and asthma risk. Additional studies are required to validate these results and investigate causal relationships in various populations.
DOI: 10.6084/m9.figshare.27015370
title: Causal links between immune cells and asthma: Insights from a Mendelian Randomization analysis

description: Recent studies suggest immunophenotypes may play a role in asthma, but their causal relationship has not been thoroughly examined. We used single nucleotide polymorphism (SNP)-derived instrumental variables. Summary data from 731 immune cell profiles and asthma cases were analyzed from genome-wide association studies (GWAS) of European populations. Mendelian Randomization (MR) analyses included inverse variance weighted (IVW), weighted median, and MR–Egger methods. Pleiotropy was assessed using the MR-Egger intercept and MR pleiotropy residual sum and outlier (MR-PRESSO) tests. Reverse MR analysis explored bidirectional causation between asthma and immunophenotypes. All statistical analyses were conducted using R software. MR analysis identified 108 immune signatures potentially contributing to asthma. Two immunophenotypes were significantly associated with asthma risk: CD4+ secreting Treg cells in allergic asthma (OR<sub>IVW</sub> = 1.078; 95% CI: 1.036–1.122; P<sub>IVW</sub> = 0.0002) and IgD + CD38− %lymphocyte cells in non-allergic asthma (OR<sub>IVW</sub> = 1.123; 95% CI: 1.057–1.194; P<sub>IVW</sub> = 0.0002). This study highlights the causal associations between specific immunophenotypes and asthma risk, providing new insights into asthma pathogenesis.
DOI: 10.6084/m9.figshare.27015370.v2
title: Causal links between immune cells and asthma: Insights from a Mendelian Randomization analysis

description: Recent studies suggest immunophenotypes may play a role in asthma, but their causal relationship has not been thoroughly examined. We used single nucleotide polymorphism (SNP)-derived instrumental variables. Summary data from 731 immune cell profiles and asthma cases were analyzed from genome-wide association studies (GWAS) of European populations. Mendelian Randomization (MR) analyses included inverse variance weighted (IVW), weighted median, and MR–Egger methods. Pleiotropy was assessed using the MR-Egger intercept and MR pleiotropy residual sum and outlier (MR-PRESSO) tests. Reverse MR analysis explored bidirectional causation between asthma and immunophenotypes. All statistical analyses were conducted using R software. MR analysis identified 108 immune signatures potentially contributing to asthma. Two immunophenotypes were significantly associated with asthma risk: CD4+ secreting Treg cells in allergic asthma (OR<sub>IVW</sub> = 1.078; 95% CI: 1.036–1.122; P<sub>IVW</sub> = 0.0002) and IgD + CD38− %lymphocyte cells in non-allergic asthma (OR<sub>IVW</sub> = 1.123; 95% CI: 1.057–1.194; P<sub>IVW</sub> = 0.0002). This study highlights the causal associations between specific immunophenotypes and asthma risk, providing new insights into asthma pathogenesis.
DOI: 10.6084/m9.figshare.26879063
title: Evaluating the timing of triple therapy initiation for the treatment of asthma in Japan: prompt versus delayed

description: In Japan, the optimal initiation timing and efficacy of single-inhaler triple therapy (SITT) in asthma management remain unexplored. This study investigated SITT initiation timing following an asthma exacerbation, and examined patient demographics and clinical characteristics. Observational, retrospective cohort study in patients with asthma aged ≥15 years who initiated SITT following their earliest observed asthma exacerbation (February–November 2021), using data from Japanese health insurance claims databases (JMDC and Medical Data Vision [MDV]). The study period ended May 2022 for JMDC and September 2022 for MDV. Descriptive analyses were performed independently by database. Variables evaluated included timing of SITT initiation post exacerbation (prompt, delayed and late, ≤30, 31–180 and &gt;180 days post index, respectively), patient demographics, clinical characteristics, and pre-index treatment. Of patients in the JMDC and MDV databases, most initiated SITT promptly after an asthma exacerbation, 60.8% (<i>n</i> = 951/1565) and 44.4% (<i>n</i> = 241/543), respectively. Delayed initiation occurred in 22.6% (<i>n</i> = 354/1565) and 26.3% (<i>n</i> = 143/543) of patients, and late initiation occurred in 16.6% (<i>n</i> = 260/1565) and 29.3% (<i>n</i> = 159/543), respectively. Most patients were indexed on a moderate asthma-related exacerbation, 97.1% (<i>n</i> = 1519/1565) and 68.7% (<i>n</i> = 373/543), respectively. Most patients with asthma initiated SITT promptly following a moderate exacerbation, with delayed and late initiation more common among patients with complex clinical profiles. The findings underscore the necessity for future research to examine the interaction between patient characteristics, clinical outcomes, and the timing of SITT initiation to optimize treatment strategies, as clinical practice may vary by exacerbation severity.
DOI: 10.6084/m9.figshare.26879063.v1
title: Evaluating the timing of triple therapy initiation for the treatment of asthma in Japan: prompt versus delayed

description: In Japan, the optimal initiation timing and efficacy of single-inhaler triple therapy (SITT) in asthma management remain unexplored. This study investigated SITT initiation timing following an asthma exacerbation, and examined patient demographics and clinical characteristics. Observational, retrospective cohort study in patients with asthma aged ≥15 years who initiated SITT following their earliest observed asthma exacerbation (February–November 2021), using data from Japanese health insurance claims databases (JMDC and Medical Data Vision [MDV]). The study period ended May 2022 for JMDC and September 2022 for MDV. Descriptive analyses were performed independently by database. Variables evaluated included timing of SITT initiation post exacerbation (prompt, delayed and late, ≤30, 31–180 and &gt;180 days post index, respectively), patient demographics, clinical characteristics, and pre-index treatment. Of patients in the JMDC and MDV databases, most initiated SITT promptly after an asthma exacerbation, 60.8% (<i>n</i> = 951/1565) and 44.4% (<i>n</i> = 241/543), respectively. Delayed initiation occurred in 22.6% (<i>n</i> = 354/1565) and 26.3% (<i>n</i> = 143/543) of patients, and late initiation occurred in 16.6% (<i>n</i> = 260/1565) and 29.3% (<i>n</i> = 159/543), respectively. Most patients were indexed on a moderate asthma-related exacerbation, 97.1% (<i>n</i> = 1519/1565) and 68.7% (<i>n</i> = 373/543), respectively. Most patients with asthma initiated SITT promptly following a moderate exacerbation, with delayed and late initiation more common among patients with complex clinical profiles. The findings underscore the necessity for future research to examine the interaction between patient characteristics, clinical outcomes, and the timing of SITT initiation to optimize treatment strategies, as clinical practice may vary by exacerbation severity.
DOI: 10.6084/m9.figshare.27015370.v1
title: Causal Links between Immune Cells and Asthma: Insights from a Mendelian Randomization Analysis

description: Recent studies suggest immunophenotypes may play a role in asthma, but their causal relationship has not been thoroughly examined. We used single nucleotide polymorphism (SNP)-derived instrumental variables. Summary data from 731 immune cell profiles and asthma cases were analyzed from genome-wide association studies (GWAS) of European populations. Mendelian Randomization (MR) analyses included inverse variance weighted (IVW), weighted median, and MR–Egger methods. Pleiotropy was assessed using the MR-Egger intercept and MR pleiotropy residual sum and outlier (MR-PRESSO) tests. Reverse MR analysis explored bidirectional causation between asthma and immunophenotypes. All statistical analyses were conducted using R software. MR analysis identified 108 immune signatures potentially contributing to asthma. Two immunophenotypes were significantly associated with asthma risk: CD4+ secreting Treg cells in allergic asthma (OR<sub>IVW</sub> =1.078; 95% CI: 1.036–1.122; P<sub>IVW</sub> =0.0002) and IgD + CD38- %lymphocyte cells in non-allergic asthma (OR<sub>IVW</sub> =1.123; 95% CI: 1.057–1.194; P<sub>IVW</sub> =0.0002). This study highlights the causal associations between specific immunophenotypes and asthma risk, providing new insights into asthma pathogenesis.